Difference between revisions of "Filanesib (ARRY-520)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
||
| Line 3: | Line 3: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category: | + | [[Category:Chemotherapeutic]] |
[[Category:KSP inhibitors]] | [[Category:KSP inhibitors]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 17:35, 3 February 2019
Mechanism of action
From the NCI Drug Dictionary: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.